Physician profile
Lance A Manning
NPI 1255445102
$2,493.58
in general payments reported to CMS, 2019-2025
24 companies · $127 in 2025
The $127 reported for 2025 was less than what a typical Otolaryngology provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $276 · 2020: $118 · 2021: $915 · 2022: $673 · 2023: $128 · 2024: $256 · 2025: $127.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $512.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $511.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $609.77 | 2019-2022 | |
| Intersect Ent, INC. | $359.90 | 2019-2022 | |
| Aerin Medical INC. | $222.56 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $179.23 | 2019-2024 | Dupixent, Libtayo |
| Acclarent, INC | $163.05 | 2019-2022 | |
| Glaxosmithkline, LLC. | $160.10 | 2021-2024 | Nucala |
| Neurent Medical Limited | $127.12 | 2025 | Neuromark Radiofrequency Console, Neuromark System |
| Ethicon US, LLC | $120.51 | 2019-2021 | |
| Karl Storz Endoscopy-America | $74.02 | 2022 | |
| Medtronic, INC. | $72.96 | 2021-2024 | Propel, Stealthstation S8 Platform, Ligasure |
| Genzyme Corporation | $67.26 | 2022-2024 | |
| Merck Sharp & Dohme LLC | $49.74 | 2021-2023 | |
| Sanofi-Aventis U.S. LLC | $45.59 | 2021 | |
| Cochlear Americas | $33.53 | 2019 | |
| Smith+Nephew, INC. | $27.04 | 2024 | Grafix |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.75 | 2021-2022 | |
| Polynovo North America LLC | $25.98 | 2024 | Novosorb Btm |
| Csl Behring | $22.20 | 2023 | Kcentra |
| Actelion Pharmaceuticals US, INC. | $21.31 | 2024 | Opsumit, Uptravi |
| Integra Lifesciences Corporation | $19.69 | 2024 | Codman Isocool Aht, Microfrance, Instruments-Orthopedic |
| United Therapeutics Corporation | $19.28 | 2024 | Tyvaso |
| Philips North America LLC | $15.43 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $15.31 | 2022 | |
| Kaleo, INC. | $15.25 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lance Manning listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.